August 2014

Aegerion Pharmaceuticals, Inc. Prices $300 Million Convertible Senior Notes … – MarketWatch

Aegerion Pharmaceuticals, Inc. Prices $300 Million Convertible Senior Notes …MarketWatchThe warrant transactions could have a dilutive effect to the extent that the market price per share of Aegerion’s common stock exceeds the applicable strike price of the warrants on any expiration date of the warrants. In addition, if the initial … and more …read more

Aegerion Pharmaceuticals, Inc. Prices $300 Million Convertible Senior Notes … – MarketWatch Read More »

BioTime Announces Second Quarter 2014 Results and Recent Developments – Wall Street Journal

BioTime Announces Second Quarter 2014 Results and Recent DevelopmentsWall Street JournalIn addition, BioTime’s subsidiary Asterias received $12.5 million in June 2014 through the sale of 5,000,000 BioTime common shares, with warrants to purchase 5,000,000 shares of Asterias Series B common stock, to two private investors who are long-term … and more …read more

BioTime Announces Second Quarter 2014 Results and Recent Developments – Wall Street Journal Read More »

uSell.com Prices $4.65 Million Registered Direct Offering – Wall Street Journal

uSell.com Prices $4.65 Million Registered Direct OfferingWall Street JournalA registration statement relating to the shares of common stock and warrants to be issued in the offering has been filed with the Securities and Exchange Commission (“SEC”) and is effective. A final prospectus relating to the offering will be filed … …read more

uSell.com Prices $4.65 Million Registered Direct Offering – Wall Street Journal Read More »

uSell.com Prices $4.65 Million Registered Direct Offering – Marketwired (press release)

uSell.com Prices $4.65 Million Registered Direct OfferingMarketwired (press release)A registration statement relating to the shares of common stock and warrants to be issued in the offering has been filed with the Securities and Exchange Commission (“SEC”) and is effective. A final prospectus relating to the offering will be filed … and more …read more

uSell.com Prices $4.65 Million Registered Direct Offering – Marketwired (press release) Read More »

uSell.com Prices $4.65 Million Registered Direct Offering – MarketWatch

uSell.com Prices $4.65 Million Registered Direct OfferingMarketWatchA registration statement relating to the shares of common stock and warrants to be issued in the offering has been filed with the Securities and Exchange Commission (“SEC”) and is effective. A final prospectus relating to the offering will be filed … …read more

uSell.com Prices $4.65 Million Registered Direct Offering – MarketWatch Read More »

Apricus Biosciences Enters Into Common Stock Purchase Agreement With … – Wall Street Journal

Apricus Biosciences Enters Into Common Stock Purchase Agreement With …Wall Street JournalNo warrants are associated with this agreement. “This agreement with Aspire Capital will enable Apricus to sell shares from time-to-time on … Any sales of shares of common stock to Aspire Capital pursuant to the purchase agreement have been or will … and more

Apricus Biosciences Enters Into Common Stock Purchase Agreement With … – Wall Street Journal Read More »

Apricus Biosciences Enters Into Common Stock Purchase Agreement With … – Wall Street Journal

Apricus Biosciences Enters Into Common Stock Purchase Agreement With …Wall Street JournalNo warrants are associated with this agreement. “This agreement with Aspire Capital will enable Apricus to sell shares from time-to-time on … Any sales of shares of common stock to Aspire Capital pursuant to the purchase agreement have been or will … and more

Apricus Biosciences Enters Into Common Stock Purchase Agreement With … – Wall Street Journal Read More »

Apricus Biosciences Enters Into Common Stock Purchase Agreement With … – MarketWatch

Apricus Biosciences Enters Into Common Stock Purchase Agreement With …MarketWatchApricus Biosciences, Inc. (NASDAQ:APRI) (the “Company” or “Apricus”), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced it has entered into a common stock purchase agreement with Aspire Capital … and more …read more

Apricus Biosciences Enters Into Common Stock Purchase Agreement With … – MarketWatch Read More »

Apricus Biosciences Enters Into Common Stock Purchase Agreement With … – MarketWatch

Apricus Biosciences Enters Into Common Stock Purchase Agreement With …MarketWatchApricus Biosciences, Inc. (NASDAQ:APRI) (the “Company” or “Apricus”), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced it has entered into a common stock purchase agreement with Aspire Capital … and more …read more

Apricus Biosciences Enters Into Common Stock Purchase Agreement With … – MarketWatch Read More »

Scroll to Top